GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scinopharm Taiwan Ltd (TPE:1789) » Definitions » Cyclically Adjusted PS Ratio

Scinopharm Taiwan (TPE:1789) Cyclically Adjusted PS Ratio : 4.39 (As of Dec. 16, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Scinopharm Taiwan Cyclically Adjusted PS Ratio?

As of today (2024-12-16), Scinopharm Taiwan's current share price is NT$22.20. Scinopharm Taiwan's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was NT$5.06. Scinopharm Taiwan's Cyclically Adjusted PS Ratio for today is 4.39.

The historical rank and industry rank for Scinopharm Taiwan's Cyclically Adjusted PS Ratio or its related term are showing as below:

TPE:1789' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.07   Med: 4.89   Max: 7.18
Current: 4.38

During the past years, Scinopharm Taiwan's highest Cyclically Adjusted PS Ratio was 7.18. The lowest was 4.07. And the median was 4.89.

TPE:1789's Cyclically Adjusted PS Ratio is ranked worse than
74.96% of 639 companies
in the Drug Manufacturers industry
Industry Median: 2.55 vs TPE:1789: 4.38

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Scinopharm Taiwan's adjusted revenue per share data for the three months ended in Sep. 2024 was NT$0.802. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is NT$5.06 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Scinopharm Taiwan Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Scinopharm Taiwan's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinopharm Taiwan Cyclically Adjusted PS Ratio Chart

Scinopharm Taiwan Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.84 5.41 4.55 4.68 5.10

Scinopharm Taiwan Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.21 5.10 5.33 5.64 5.07

Competitive Comparison of Scinopharm Taiwan's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinopharm Taiwan's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Scinopharm Taiwan's Cyclically Adjusted PS Ratio falls into.



Scinopharm Taiwan Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Scinopharm Taiwan's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=22.20/5.06
=4.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Scinopharm Taiwan's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.802/133.0289*133.0289
=0.802

Current CPI (Sep. 2024) = 133.0289.

Scinopharm Taiwan Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 1.075 99.070 1.443
201503 1.238 99.621 1.653
201506 1.212 100.684 1.601
201509 1.262 100.392 1.672
201512 1.293 99.792 1.724
201603 1.288 100.470 1.705
201606 1.287 101.688 1.684
201609 1.258 101.861 1.643
201612 1.260 101.863 1.646
201703 1.159 102.862 1.499
201706 1.112 103.349 1.431
201709 1.111 104.136 1.419
201712 1.130 104.011 1.445
201803 1.087 105.290 1.373
201806 1.278 106.317 1.599
201809 0.990 106.507 1.237
201812 1.081 105.998 1.357
201903 0.974 107.251 1.208
201906 0.757 108.070 0.932
201909 0.849 108.329 1.043
201912 1.036 108.420 1.271
202003 0.685 108.902 0.837
202006 1.120 108.767 1.370
202009 0.992 109.815 1.202
202012 1.103 109.897 1.335
202103 0.809 111.754 0.963
202106 0.907 114.631 1.053
202109 0.741 115.734 0.852
202112 0.907 117.630 1.026
202203 0.932 121.301 1.022
202206 0.991 125.017 1.055
202209 0.931 125.227 0.989
202212 1.280 125.222 1.360
202303 0.819 127.348 0.856
202306 0.928 128.729 0.959
202309 0.859 129.860 0.880
202312 1.414 129.419 1.453
202403 1.116 131.776 1.127
202406 0.916 132.554 0.919
202409 0.802 133.029 0.802

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Scinopharm Taiwan  (TPE:1789) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Scinopharm Taiwan Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Scinopharm Taiwan's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinopharm Taiwan Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is primarily engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. Schinopharm also conducts consulting and technical services. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.

Scinopharm Taiwan Headlines

No Headlines